Skip to content

Moderate Alcohol Consumption, Fat and Carbohydrate Metabolism and Insulin Sensitivity

The Effect of Moderate Alcohol Consumption on Markers of Oxidative Phosphorylation and Lipid Oxidation and on Postprandial Glycemic Control in Healthy, Lean and Overweight, Young Men

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00364767
Enrollment
19
Registered
2006-08-16
Start date
2004-10-31
Completion date
2004-12-31
Last updated
2008-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2, Cardiovascular Disease

Keywords

Moderate alcohol consumption, Fat and carbohydrate oxidative capacity, Postprandial glycemic response

Brief summary

Moderate alcohol consumption is associated with a decreased risk of diabetes type 2. This association could be mediated by an improvement of insulin sensitivity with moderate alcohol consumption. Patients with diabetes type 2 or impaired glucose tolerance often may have decreased fat oxidative capacity or oxidative phosphorylation in tissue such as muscle. This could lead to accumulation triglyceride storage in muscle, which could interfere with insulin signaling. Whether such mechanism can also play a role with moderate alcohol consumption is unknown and will be investigated in this study. In addition, moderate alcohol consumption with a meal can lead to delayed hypoglycemia in type 1 diabetes patients. How moderate alcohol consumption affects postprandial glycemic response in healthy subjects is unknown. This is a secondary objective of this trial.

Detailed description

To investigate the effect of moderate alcohol consumption on * enzymes involved in fatty acid oxidation, oxidative phosphorylation and glycolysis in skeletal muscle * transporters of fatty acids and glucose in fat tissue * post-prandial glycemic response in healthy, lean or overweight, young men Design : Open, randomized, partially diet-controlled, placebo controlled cross-over design Participants * Description : Healthy, lean and overweight young (18-40 years) men * Number : 20 Study substances * Test substance : 100 ml whiskey (Famous Grouse, 40% v/v alcohol: ≈ 32 g alcohol) * Reference substance : 100 ml mineral water (Spa blauw) Duration: 2 treatment periods of 4 weeks (28 days) Test parameters: * Muscle biopsy for activity of 3-hydroxy fatty-acyl CoA dehydrogenase, citrate synthase, cytochrome c oxidase * Postprandial glycemic response (glucose, insulin, GLP-1, GLP-2, GIP, glucagon, FFA etc.) * Insulin sensitivity and related factors (oral glucose tolerance test, adiponectin, HbA1c) * Liver enzymes (safety) * Body weight * Urinary ethyl glucuronide (compliance)

Interventions

DIETARY_SUPPLEMENTA

Alcohol consumption (32 g/day) for 4 weeks

DIETARY_SUPPLEMENTB

Water

Sponsors

Dutch Foundation for alcohol research
CollaboratorUNKNOWN
TNO
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy men aged between 18 and 40 years * Lean subjects BMI 18.5-25 kg/m2 and overweight/obese subjects BMI \>27 kg/m2 (including 18.5, 25 and 27) * Alcohol consumption between 7 and 28 units/week (including 7 and 28)

Exclusion criteria

* Smoking * Family history of alcoholism * History of medical or surgical events that may significantly affect the study outcome, particularly metabolic or endocrine disorders and gastrointestinal disorders * Recent blood donation * More than 8 hours/week of intense exercise * Blood haemoglobin concentration below 8.4 mmol/l * Allergic to betadine or lidocaine.

Design outcomes

Primary

MeasureTime frame
enzymes involved in fatty acid oxidation, oxidative phosphorylation and glycolysis in skeletal muscle4 weeks

Secondary

MeasureTime frame
Post-prandial glycemic response4 weeks
insulin sensitivity (oral glucose tolerance test) and related factors (adiponectin, HbA1c)4 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026